trending Market Intelligence /marketintelligence/en/news-insights/trending/jh0iadqchr9flzxstug05a2 content esgSubNav
Log in to other products

 /


Looking for more?

Contact Us
In This List

China Biologic names CEO

Blog

Global M&A Infographic Q1 2021

Blog

Q1 2021 Global Capital Markets Activity: SPAC IPOs, Issuance in Consumer Discretionary Sector Surge

Blog

COVID-19 Impact & Recovery: Private Equity

COVID-19 Impact & Recovery: Corporates


China Biologic names CEO

Beijing-based biopharmaceutical company China Biologic Products Holdings Inc. appointed Bing Li as its CEO.

Li replaces Zhijun Tong, the blood plasma-based biopharmaceutical company's acting CEO. Tong will continue as an executive director and president of the company.

Li rejoined the China Biologic board on July 25, having previously been a director of the company from February 2011 to May 2014.

The new CEO has experience as managing director of Fosun Group, a China-based international conglomerate and investment company, from March 2016 to December 2017, and a vice president of Shanghai Fosun Pharmaceutical (Group) Co. Ltd., a Chinese pharmaceutical company, from May 2014 to February 2016.